디지털 호흡 기기 시장 예측(-2030년) : 제품별, 질환별, 유통 채널별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Digital Respiratory Devices Market is accounted for $46.5 billion in 2023 and is expected to reach $254.9 billion by 2030 growing at a CAGR of 27.5% during the forecast period. The Digital Respiratory Devices is the healthcare sector involving the development and utilization of digital technologies to monitor and manage respiratory conditions. These devices are designed to assist in the diagnosis, treatment, and ongoing management of diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders. Their uses include real-time monitoring of lung function, medication adherence tracking, and remote patient management.

According to the World Health Organization prediction (2020), COPD will surpass ischemic heart disease and HIV/AIDS to become the fourth-leading causes of death, respectively, by 2030.

Market Dynamics:

Driver:

Increasing prevalence of respiratory diseases

Conditions like asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea are on the rise, leading to a growing need for innovative solutions to monitor, manage, and improve respiratory health. Digital respiratory devices offer real-time monitoring, data collection, and personalized treatment plans, empowering patients and healthcare providers to effectively address these conditions. With the burden of respiratory diseases becoming more pronounced, these devices play a vital role in enhancing patient care, early intervention, and self-management, ultimately improving the quality of life for individuals affected by such conditions and driving market growth.

Restraint:

Compatibility and integration with existing healthcare systems

Health systems often use various electronic health records (EHR) and data management platforms, which may not readily accommodate or communicate with new digital respiratory devices. This lack of interoperability hinders the seamless exchange of patient data, making it difficult for healthcare providers to incorporate device-generated information into patient records and treatment plans. Overcoming this restraint requires standardized data formats, improved communication protocols, and collaborative efforts to ensure that digital respiratory devices can seamlessly integrate with existing healthcare systems, enabling more effective patient care and data-driven interventions.

Opportunity:

Growth of telehealth and remote patient monitoring technologies

These technologies have become integral in healthcare, offering real-time remote monitoring of respiratory conditions. Digital respiratory devices are well-positioned to leverage this trend by providing patients with the means to measure and transmit vital respiratory data to healthcare providers, facilitating remote consultations and proactive care. This not only enhances patient convenience but also improves early detection of exacerbations and supports personalized treatment plans. The integration of digital respiratory devices into telehealth platforms aligns with the evolving healthcare landscape, offering a patient-centric approach and expanding the market's potential for improved respiratory care.

Threat:

Data privacy and security concerns

With the collection and transmission of sensitive patient health data, there is an increased risk of data breaches and unauthorized access, which can have serious consequences for patient privacy. Regulatory compliance and robust cybersecurity measures are paramount to safeguarding this data. The threat of breaches or data misuse can erode patient trust and hinder the adoption of digital respiratory devices. Overcoming this threat requires stringent data protection measures, encryption protocols, and comprehensive data security strategies to ensure patient information remains confidential and secure, thereby preserving the integrity of digital respiratory healthcare solutions.

COVID-19 Impact:

The COVID-19 pandemic had a significant impact on the market. With respiratory health at the forefront of global concerns, the demand for remote monitoring and telehealth solutions, including digital respiratory devices, surged. These devices allowed healthcare providers to remotely monitor and manage respiratory conditions while minimizing in-person contact, reducing the risk of virus transmission. The pandemic accelerated the adoption of these technologies, making them an essential component of the healthcare ecosystem. Additionally, they focus on respiratory health during the pandemic created greater awareness and acceptance of digital respiratory devices among both healthcare providers and patients.

The nebulizers segment is expected to be the largest during the forecast period

The nebulizers segment is expected to have a lucrative growth. These devices are widely used for treating various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). Digital nebulizers offer advantages such as precise dosage delivery, enhanced portability, and data connectivity for remote monitoring and treatment adjustment. They empower patients to manage their respiratory health more effectively, improve medication adherence, and enable healthcare providers to monitor treatment compliance remotely. Digital nebulizers are instrumental in enhancing patient outcomes and reducing the burden of respiratory diseases, driving their adoption in the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These healthcare facilities rely on digital respiratory devices for the precise diagnosis, monitoring, and treatment of patients with respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea. Digital respiratory devices enhance patient care by providing real-time data on lung function, medication adherence, and treatment effectiveness. They enable healthcare professionals to make informed decisions and adjust treatment plans promptly. The use of these devices in hospitals not only improves patient outcomes but also contributes to the overall efficiency and quality of respiratory care, making them integral components of the healthcare ecosystem.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region comprises the United States and Canada, where an aging population, environmental factors, and lifestyle-related conditions contribute to the growing burden of respiratory ailments. Digital respiratory devices are widely adopted in North America, offering advanced solutions for monitoring, diagnosing, and managing these conditions. Moreover, the region's investment in telehealth and remote monitoring technologies has accelerated the integration of digital respiratory devices into the healthcare ecosystem. North America's commitment to innovation and healthcare excellence positions it as a key driver in the global digital respiratory devices market.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. With a vast and growing population, there is an increasing prevalence of respiratory diseases in countries like China and India. The region is witnessing significant investments in healthcare infrastructure and the adoption of digital health technologies, including digital respiratory devices. These devices enable healthcare providers to reach a wider patient base, especially in remote areas, and enhance the management of respiratory conditions. Moreover, the Asia Pacific's focus on telehealth, remote patient monitoring, and personalized healthcare positions it as a dynamic and expanding market for digital respiratory devices, offering significant potential for improving respiratory care and patient outcomes.

Key players in the market

Some of the key players in Digital Respiratory Devices market include: 3M Health Care Limited, Adherium Limited, AireHealth, Inc., Amiko Digital Health Limited, Cognita Labs, COHERO Health Inc., FindAir Sp. z o.o, Novartis AG, Pneuma Respiratory Inc., Propeller Health and Teva Pharmaceuticals Industries Ltd.

Key Developments:

In February 2023, Adherium Limited, a market leader in respiratory eHealth, remote monitoring, and data management, announced that the FDA's 510(k) approval has allowed it to begin selling its first, next-generation Hailie Sensor, which includes physiological measures for tracking the use of asthma and COPD medications.

In September 2022, Propeller Health expanded their pharmacy refill app to cover CVS, Rite-Aid, Kroger, and Walmart pharmacies.

In July 2022, Propeller Health also launched My Drugstore, an in-app service in collaboration with Walgreens that allows clients to manage their medication refills for COPD and asthma and locate a nearby pharmacy.

Products Covered:

• Respiratory Consumables
• Nebulizers
• Oxygen Concentrators
• Positive Airway Pressure (PAP) Devices
• Polysomnography Devices
• Ambulatory PSG Devices
• Clinical PSG Devices
• Pulse Oximeters
• Mechanical Ventilators
• Spirometers
• Other Products

Diseases Covered:

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Other Diseases

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

End Users Covered:

• Hospitals
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Respiratory Devices Market, By Product

• 5.1 Introduction
• 5.2 Respiratory Consumables
  • 5.2.1 Respiratory Mask
  • 5.2.2 Nasal Cannulas
  • 5.2.3 Oxygen Tubing Sets
  • 5.2.4 Breathing Filters
• 5.3 Nebulizers
  • 5.3.1 Compressed Jet Nebulizers
  • 5.3.2 Ultrasonic Nebulizers
  • 5.3.3 Other Nebulizers
• 5.4 Oxygen Concentrators
  • 5.4.1 Home Oxygen Concentrators
  • 5.4.2 Portable Oxygen Concentrators
• 5.5 Positive Airway Pressure (PAP) Devices
• 5.6 Polysomnography Devices
• 5.7 Ambulatory PSG Devices
• 5.8 Clinical PSG Devices
• 5.9 Pulse Oximeters
• 5.10 Mechanical Ventilators
• 5.11 Spirometers
• 5.12 Other Products

6 Global Digital Respiratory Devices Market, By Disease

• 6.1 Introduction
• 6.2 Asthma
• 6.3 Chronic Obstructive Pulmonary Disease (COPD)
• 6.4 Other Diseases

7 Global Digital Respiratory Devices Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.5 Other Distribution Channels

8 Global Digital Respiratory Devices Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Homecare Settings
• 8.4 Other End Users

9 Global Digital Respiratory Devices Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 3M Health Care Limited
• 11.2 Adherium Limited
• 11.3 AireHealth, Inc.
• 11.4 Amiko Digital Health Limited
• 11.5 Cognita Labs
• 11.6 COHERO Health Inc.
• 11.7 FindAir Sp. z o.o
• 11.8 Novartis AG
• 11.9 Pneuma Respiratory Inc.
• 11.10 Propeller Health
• 11.11 Teva Pharmaceuticals Industries Ltd.